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Abstract 
 
Background:  Acute bronchitis management continues to be mistreated.  Evidence based 
practice guidelines do not support antibiotic therapy for the treatment of acute bronchitis.  
Providers are encouraged to prescribe antitussives, suppressants and inhaler medications for the 
treatment of acute bronchitis symptoms, including cough.  
Objective: The overall objective of this project is to evaluate the management of adults 
diagnosed with acute bronchitis in a limited services clinic. 
Methods:  A retrospective chart review was conducted on patients in a limited services clinic.  
The chart review assessed patients aged 18-64 with a diagnosis of acute bronchitis from July 1, 
2016- June 30, 2017.   
Results:  Of adult patients with acute bronchitis, 31% of adults aged 18-64 were not prescribed 
an antibiotic (N=10/32) and 68% were prescribed at least one antibiotic.  Various medication 
classes were prescribed to patients with acute bronchitis, including analgesics, bronchodilators, 
antihistamines, antibiotics, corticosteroids, cough/cold/allergy medications, nasal agents and 
mouth/throat agents. 
Conclusions: Antibiotic therapy was highly prescribed for patients with the diagnosis of acute 
bronchitis.  However, 34% of adults with a diagnosis of acute bronchitis had at least one 
comorbid condition, such as chronic smoker, asthma or COPD. Among those with a comorbid 
condition, 82% (N=11; 9/11) were prescribed an antibiotic. 
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An Evaluation of Provider Adherence to Acute Bronchitis Quality Measures in Adults 
 
Introduction 
 
 Acute bronchitis is one of the most common conditions encountered in clinical practice in 
adults.  Approximately 100 million (10%) ambulatory care visits in the United States are related 
to a diagnosis of acute bronchitis (Harris, Hicks & Quaseem, 2016).  Acute bronchitis is caused 
by a respiratory virus, such as an upper respiratory virus, cold or the flu.  Symptoms of acute 
bronchitis include a cough lasting at least five days, coughing with mucus, a runny or stuffy 
nose, fever and wheezing (American Lung Association, 2018).  Risk factors for acute bronchitis 
include a current smoker, or second hand smoke exposure. Furthermore, close contact with 
someone that has acute bronchitis is another risk factor (American Lung Association, 2018).   
Acute bronchitis is often a diagnosis that is not treated appropriately.  Antibiotic use is 
not recommended for individuals diagnosed with acute bronchitis (Kinkade & Long, 2016); 
however, many providers continue to prescribe antibiotics. The Merit-based Incentive Payment 
System (MIPS) of the Centers for Medicare & Medicaid Services (CMS) Quality Payment 
Program focuses on rewarding providers for high quality of care.   
 The Merit-based Incentive Payment System (MIPS) pays for Medicare Part B items and 
services.  Clinicians may receive an increase or decrease on their payments, based on their 
performance.  MIPS was designed to link payments to quality of care, improve health outcomes 
and reduce the cost of care (US Department of Health and Human Services [USDHHS], 2016).  
The Centers for Medicare & Medicaid Services (CMS) is a division of the US Department of 
Health and Human Services, and developed the MIPS measures.  One of the quality measures of 
MIPS is avoidance of antibiotic treatment in adults with acute bronchitis (UHSDHHS, 2016). 
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The criteria for the measure includes adults aged 18-64 years, a diagnosis with acute bronchitis 
and antibiotics not prescribed during the patient encounter. Moreover, patients with a 
comorbidity, such as, chronic obstructive pulmonary disease or chronic bronchitis, are excluded 
from the MIPS measure (USDHHS, 2016).   
The overall objective of this project was to evaluate the management of adults diagnosed 
with acute bronchitis in a limited services clinic.  A retrospective chart audit was completed for 
patients diagnosed with acute bronchitis from June 30, 2016 through July 1, 2017. 
 
Background  
 
Acute bronchitis is a clinical condition characterized by a cough, with or without sputum 
production lasting at least five days and typically resolving within one to three weeks (Kinkade 
& Long, 2016).  It is characterized by inflammation of the trachea and large airways of the 
respiratory tract and is most commonly due to viral infections. Appropriate management and 
treatment for acute bronchitis is imperative to prevent complications from antibiotic use.   
Treatment for acute bronchitis includes patient education and discussing the course of the 
illness with the patient. Symptom control for patients experiencing a cough should be part of the 
treatment (Kinkade & Long, 2016). Common therapies for symptom management include 
antitussives, expectorants, inhaler medications and alternative therapies, such as the use of 
echinacea, pelargonium and honey (Albert, 2010); however, antibiotics are not recommended for 
the treatment of acute bronchitis (McKay, Mah, Law, McGrail & Patrick, 2016). Providers are 
encouraged to discuss the risks of antibiotic overuse for patients seeking antibiotic treatment. 
Antibiotics can increase adverse effects and cause severe complications such as Clostridium 
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difficile (American Board of Internal Medicine, 2017; Malesker, Callahan-Lyon, Ireland & 
Irwin, 2017; Smith, Fahey, Smucny, & Becker, 2017).  
Research studies have shown antibiotics do not provide a benefit for patients with acute 
bronchitis (Harris, Hicks & Qaseem, 2016; Irwin, French, Chang, & Altman, 2018; Little, 
Rumsby, Kelly, Watson, Moore, Warner, Fahey & Williamson, 2005; Smith, Fahey & Becker, 
2017). Little et al., (2005), conducted a randomized controlled trial to evaluate patients 
diagnosed with acute bronchitis, and whether antibiotics made a difference in symptoms.  They 
found no difference in symptoms severity in adults treated with amoxicillin in comparison to 
those taking a placebo (Little et al., 2005). Antibiotic use has been associated with increased 
adverse effects when compared to those taking a placebo.  Antibiotic use has been associated 
with increased adverse effects such as nausea, vomiting, diarrhea, rash, headaches and vaginitis 
(Little et al., 2005; Smith et al., 2017).  A cohort study identified increased complication rates 
associated with antibiotic use in patients with acute cough lasting <3 weeks without evidence of 
pneumonia. Complications included hospital admission and death (Little et al., 2017). 
Unnecessary antibiotic use can also cause antibiotic resistant organisms that can harm the patient 
and the community (Khanna & Tosh, 2014; Langdon, Crook & Dantas, 2016).  
In an effort to improve patient care delivery and reward clinicians for providing quality 
patient care, the Centers for Medicare & Medicaid Services (CMS) implemented the Quality 
Payment Program in 2017. The program encourages providers to focus on quality of care and 
making patients healthier. The Quality Payment Program was implemented by the Centers for 
Medicare & Medicaid Services (CMS) in 2017 and focuses on quality of care and rewarding 
provider’s high-value patient centered care for Medicare patients. One of the tracks of the 
Quality Payment Program is the Merit-based Incentive Payment System (MIPS). Avoidance of 
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antibiotic treatment in adults with acute bronchitis is a quality measure from the MIPS Quality 
Payment Program. The measure is met if the percentage of adults 18-64 years of age, with a 
diagnosis of acute bronchitis, were not prescribed an antibiotic. This is considered a high priority 
measure within MIPS Quality Payment Program (USDHHS, 2016).  
The current recommendation for adults age 18-64 years for acute bronchitis from The 
American College of Chest Physicians (2018) include routine treatment with antitussives, 
suppressants and inhaled medications (Irwin et al., 2018). Antibiotics are not justified treatment 
and should not be offered to patients.  In addition, thorough explanations and education should 
be offered to patients, as they may expect to receive antibiotics based on previous experiences 
and public expectation (Irwin et al., 2018).  
The purpose of this project was to evaluate the management of acute bronchitis in adults 
ages 18-64 in a limited service clinic in a small southern town.  The results of this evaluation will 
provide information regarding the degree of adherence to the MIPS quality measure related to 
acute bronchitis and will help to determine if interventions are needed to encourage adherence to 
these quality initiatives. 
Purpose 
 
The purpose of this project was to use the MIPS quality measure as a reference to evaluate 
the management of acute bronchitis in adult’s ages 18-64 years in a limited services clinic.  
Objectives include 1) determine the percentage of patients not receiving and antibiotic, 2) 
identify all medication prescribed, 3) summarize presenting symptoms and existing comorbid 
conditions, among adults aged 18 to 64 with a diagnosis of acute bronchitis between July 1, 2016 
and June 30, 2017.   
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Methods 
 
Study Design 
 
  A retrospective chart review was utilized to gather data. A descriptive study design was 
used to evaluate medical management of adult patients diagnosed with acute bronchitis in a 
limited services clinic. All subjects were seen between June 30, 2016 through July 1, 2017 at a 
limited services clinic.  This timeframe was selected to capture all patients diagnosed with acute 
bronchitis within a whole calendar year.  The University of Kentucky’s Center for Translational 
Sciences extracted data from medical records based on the project objectives.  Institutional 
Review Board (IRB) approval was obtained through the University of Kentucky IRB through an 
expedited review. De-identified information of personal health identifiers was obtained.  
 
Study Population 
 The setting was a rural, limited service clinic.  A limited services clinic is a walk in 
healthcare center staffed by nurse practitioners trained to diagnose and treat patients with 
common illnesses.  The clinic is staffed by nurse practitioners and serves a diverse patient 
population across the lifespan.    
 The population of interest included patients aged 18 through 64, with a diagnosis of acute 
bronchitis.  This age was captured in relation the MIPS recommendation for monitoring patients 
aged 18-64. Exclusions were made for patients less than 18 years of age.  There were no 
exclusions based on race, ethnicity or gender.  
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Procedure and Sample 
 A retrospective chart review of patients at a limited services clinic, ages 18 through 64 
with a diagnosis of acute bronchitis (ICD-10 code: J20.0-J20.9) was obtained.  The health 
records were obtained through the University of Kentucky Center for Clinical and Translational 
Sciences, Biomedical Informatics Group, and stored in RedCap.  All records were deidentified to 
maintain patient confidentiality.  The sample consisted of 32 patients with a medical visit 
between June 30, 2016 through July 1, 2017).  Of the 32 patients, there were 10 males and 22 
females diagnosed with acute bronchitis.  Data extracted included age, gender, ICD 10 diagnosis 
code, diagnosis name, medications, comorbidities and problem list. 
 
Statistical Analysis 
 Data analysis was performed using SPSS, version 24.  Analysis of extracted data entailed 
descriptive statistics, including frequency distributions or means and standard deviations, and 
were used to summarize study variables. The Fisher’s exact test was utilized to show among 
those with a comorbid condition, if antibiotics were prescribed.  An alpha of .05 was used to 
determine statistical significance.   
Results 
 
 During the study period, 32 patients were diagnosed with acute bronchitis by six different 
providers all of whom were Family Nurse Practitioners. The average age of patients was 38 years 
(SD=10.30; see Table 1).  Of the 32 patients, there were 10 males and 22 females diagnosed with 
acute bronchitis.  The most common presenting symptoms documented in the chart was a cough 
56% (N= 5; 5/11) . Of patients with at least one comorbid condition 82% (N=11; 9/11), the most 
common condition was asthma (31%), (N=10), followed by current smoker (25%), (N=8).  
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 The percentage of adults ages 18-64 with a diagnosis of acute bronchitis who were not 
prescribed an antibiotic was 31% (N=10; 10/32).  The percentage of adults that received one 
antibiotic was 59% (N=19; 19/32).  Adults prescribed two antibiotics were 9% (N=3; 3/32) of the 
patients (Table 2). The most common antibiotic classes prescribed were penicillin and 
macrolides. For patients prescribed two antibiotics, the following antibiotic class combinations 
were prescribed—cephalosporin and penicillin, macrolide and penicillin, and penicillin and 
penicillin.  Cold, cough and allergy medications were the most commonly prescribed 
medications (Table 3 and Figure 1). Various medication combinations were prescribed for 
patients diagnosed with acute bronchitis (Table 4). 
 Of the 32 patients in the study, (28%) 9 patients presented with symptoms. The 
presenting symptoms for adults diagnosed with acute bronchitis included cough, cough with 
productive purulent sputum, persistent cough and other respiratory symptoms. Of the 9 patients 
that had symptoms documented, five patients presented with a cough (Figure 2).  
 Of the 32 patients in the study, (34%) 11 patients had at least one underlying 
comorbidity.  The following comorbidities were identified from the participants: asthma, chronic 
obstructive pulmonary disease (COPD), current smoker, former smoker. The most common 
comorbidity was asthma, followed by current smoker (Table 5 and Figure 3).   
 Among those patients with a comorbid condition, 82% (N=11; 9/11) were prescribed an 
antibiotic.  The Fisher’s exact test of association was not significant (p=.32), therefore, 
statistically there was not an association between having a comorbid condition and antibiotic 
prescription.  
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Discussion 
  
 The limited services clinic did not practice similar antibiotic prescribing for patients 
diagnosed with acute bronchitis, when compared to The American College of Chest Physicians 
(2018) clinical practice guideline recommendations (Irwin et al., 2018).  The CHEST Expert 
Panel (Malesker, Callahan-Lyon, Ireland & Irwin, 2017) identified 65-80% of patients diagnosed 
with acute bronchitis are being prescribed antibiotics.  This is true for the sample in this study, as 
68% of patients diagnosed with acute bronchitis were prescribed antibiotics.  Antibiotic 
treatment should not be offered for patients with acute bronchitis and prescribing antibiotics 
should be limited for this population (Braman, 2006; Harris, Hicks & Qaseem, 2016; Little, 
Rumsby, Kelly, Watson, Moore, Warner, Fahey & Williamson, 2005; Smith, Fahey & Becker, 
2017).   
 
 Several patients that were diagnosed with acute bronchitis had multiple comordities.  
Additionally, it was difficult to identify how many days patients had symptoms before seeking 
medical care.   Treatment for acute bronchitis includes symptom control, as well as 
pharmacological medications including antitussives, expectorants and inhaler medications 
(Albert, 2010). The statistics above identify a need to focus on the management for acute 
bronchitis within the clinic in reducing the amount of antibiotics prescribed with a diagnosis of 
acute bronchitis. Antibiotic use is permitted in patients with a comorbidity, as patients with a 
comorbidity that are prescribed antibiotics are excluded from the MIPS measure. 
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Implications for Practice 
 
 Education for providers is key in meeting the MIPS recommendations.  There are several 
resources and tools that can be used for providers and patients on when antibiotics should be 
prescribed and alternative medications or treatments that can be used instead.  The Choosing 
Wisely campaign is a great resource and provides brochures on addressing antibiotic overuse and 
recommendations for providers on when antibiotics should be prescribed.  The Choosing Wisely 
campaign seeks to advance a national dialogue on avoiding unnecessary treatments and medical 
tests (Advancing Medical Professionalism, 2015).  Moreover, the Centers for Disease Control 
and Prevention (CDC), offers printable antibiotic prescription pads and interactive tools to 
prevent unnecessary treatment with antibiotics with their Be Antibiotics Aware campaign. This 
campaign is formerly known as the Get Smart about Antibiotics campaign.  The campaign is to 
promote a national effort to help fight antibiotic resistance and improve antibiotic prescribing use 
(Centers for Disease Control and Prevention, 2018).    
 
Implications for Future Study 
 Implications for future practice include aggregating data over several years to obtain a 
larger sample size.  Moreover, implementing the Choosing Wisely Campaign or the Be 
Antibiotics Aware campaign would be helpful for providers and patients.  In addition, it would be 
interesting to see if providers coded “bronchitis,” of “J40” instead of acute bronchitis, and did 
not specify acute or chronic.  Identifying evidence-based strategies in delayed prescribing would 
also be of interest.  Finally, appropriateness of antibiotic prescription for patients with 
comorbidities is key.  
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Limitations 
 There were several limitations identified with this study. The University of Kentucky 
Center for Clinical and Translational Sciences, Biomedical Informatics Group was operating 
under one staff member while retrieving the data for this project.  Due to having one employee 
working on this project, the staff member duplicated data.   After conversing with the data 
extractor, he recommended deleting the duplicative data. In addition, the staff member was new 
and needed to reach out to my advisor and other departments for assistance when collecting the 
data.  Secondly, being a retrospective study, information may have been inputted inaccurately 
within the electronic health record, resulting in the data to be misconstrued. Finally, data was 
collected from one facility, limiting generalization of the study. 
 
Conclusion 
 
Antibiotic treatment was utilized in this clinic for the treatment of acute bronchitis, despite 
evidence based practice guidelines. Among those without a comorbidity, 62% (N=13; 13/21) 
received antibiotics.  Among those with a comorbidity, 82% (N=11; 9/11) received antibiotics.   
Without taking the comorbidities into account, it is crucial to identify patients with acute 
bronchitis and treat patients appropriately with non-pharmacological medications, including tea 
and honey.  Moreover, pharmacological treatment is useful for symptomatic patients with a 
cough, which include expectorants, inhaled medications and antitussives. As a result, providers 
need to be aware of the MIPS recommendation of not prescribing antibiotic therapy for patients 
diagnosed with acute bronchitis.  Further education is needed for treatment guidelines for acute 
bronchitis and comorbidities.  
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Table 1: Age, Comorbidities, and Antibiotics 
 n (%) 
Age, Mean (SD) 37.59 (10.30) 
Comorbidity  
   Yes 
   No 
 
11 (34%) 
21 (66%) 
Prescribed antibiotic: 
   Yes 
   No 
 
22 (68.76%) 
10 (31.25%) 
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Table 2: Number of Antibiotics Prescribed 
 
# of Antibiotics Prescribed 
 
Frequency Percent 
0 10 31.25% 
 
1 
 
19 59.38% 
2 
 
3 9.38% 
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Table 3: Medications Prescribed by Class 
 
Medication Class 
 
Frequency Percentage 
Analgesics - Anti-
inflammatory 
 
1 1.28 
Antiasthmatic And 
Bronchodilator Agents 
 
21 26.92 
Antihistamines 
 
2 2.56 
Cephalosporins 
 
1 1.28 
Corticosteroids 
 
6 7.69 
Cough/cold/allergy 
 
20 25.64 
Fluoroquinolones 
 
2 2.56 
Macrolides 
 
10 12.82 
Mouth/Throat agents 
 
1 1.28 
Nasal Agents 
 
2 2.56 
Penicillins 
 
10 12.82 
Tetracyclines  
 
2 2.56 
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Table 4: Medication Combinations Prescribed for Acute Bronchitis 
Combination Medications by Class Prescribed Frequency Percent 
Analgesics-Anti-inflammatory/Antiasthmatic And Bronchodilator 
Agents/Antihistamines/Macrolides/Penicillins 
1 3.13 
Antiasthmatic And Bronchodilator Agents 2 6.25 
Antiasthmatic And Bronchodilator/Macrolides 1 3.13 
Antiasthmatic And Bronchodilator 
Agents/Antihistamines/Corticosteroids/Macrolides 
1 3.13 
Antiasthmatic And Bronchodilator 
Agents/Cephalosporins/Corticosteroids 
Cough/Cold/Allergy/Penicillins 
1 3.13 
Antiasthmatic And Bronchodilator Agents/Corticosteroids/ 
Cough/Cold/Allergy/Tetracyclines 
1 3.13 
Antiasthmatic And Bronchodilator 
Agents/Corticosteroids/Mouth/throat/dental Agents 
1 3.13 
Antiasthmatic And Bronchodilator Agents/Cough/Cold/Allergy  4 12.52 
Antiasthmatic And Bronchodilator 
Agents/Cough/cold/allergy/Macrolides 
1 3.13 
Antiasthmatic And Bronchodilator 
Agents/Cough/cold/allergy/Penicillins  
1 3.13 
Antiasthmatic And Bronchodilator Agents/Fluoroquinolones 1 3.13 
Antiasthmatic And Bronchodilator Agents/Macrolides 3 9.38 
Antiasthmatic And Bronchodilator Agents/Penicillins 1 3.13 
Antiasthmatic And Bronchodilator Agents/Tetracyclines 1 3.13 
Corticosteroids/Cough/cold/allergy/Nasal Agents - Systemic And 
Topical 
1 3.13 
Corticosteroids/Penicillins 1 3.13 
Cough/cold/allergy 2 6.25 
Cough/cold/allergy/Macrolides 1 3.13 
Cough/cold/allergy/Fluoroquinolones 1 3.13 
Cough/cold/allergy/Macrolides 1 3.13 
Cough/cold/allergy/Nasal Agents - Systemic And 
Topical/Penicillins 
1 3.13 
Cough/cold/allergy/Penicillins 1 3.13 
Macrolides 1 3.13 
Penicillins 2 6.25 
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Table 5: Comorbidities 
Comorbidities  Frequency Percent 
Asthma 10 31 
COPD (chronic obstructive pulmonary disease) 2 6 
Current Smoker 8 25 
Former Smoker 4 13 
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Figure 1: Medication Class and Number of Medications Prescribed Including Antibiotics  
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Figure 2: Documented Symptoms Presented 
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Figure 3: Comorbidities 
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